AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05076110
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
Trial: NCT05211232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
Trial: NCT04809623
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
Trial: NCT05390905
Drug: HSK21542 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1μg/kg/dose
Trial: NCT05390905
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05335044
Drug: EX5619
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05948813
Drug: TY-9591
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
Trial: NCT05580003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension
Trial: NCT05309200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
Trial: NCT05980507
Drug: ICI201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI201 CAR-T cell injection
Trial: NCT05357820
Drug: AB-106, Rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
Trial: NCT06299670
Drug: Combinations
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Of Thalidomide \& Hydroxyurea
Trial: NCT02533232
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 200mg per day
Trial: NCT05461053
Drug: LMX 4 Topical Cream
RxNorm normalized name: LMX 4 Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
Trial: NCT05213312
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
Trial: NCT04931524
Drug: carbon-14-[14C]-ANG-3777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
Trial: NCT05305508
Drug: Calcium Dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
Trial: NCT05794659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.d. (3-week interval, 3 cycles in total)
Trial: NCT05842382
Drug: Active Ingredient
RxNorm normalized name: TITANIUM DIOXIDE 79 mg in 1 g / ZINC OXIDE 67 mg in 1 g TOPICAL STICK [SPF 50 plus Sunscreen All Mineral Active Ingredients]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Vitamin C (12g/day)
Trial: NCT05842382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dextrose 5%
Trial: NCT03315299
Drug: ASP2215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take ASP2215 by mouth daily for 28 day cycles
Trial: NCT05732727
Drug: Antihypertensive algorithm
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive algorithm based on diuretics agents
Trial: NCT06700083
Drug: SHR-6934 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-6934 placebo
Trial: NCT05732727
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care management for antihypertensive therapy intensification
Trial: NCT05320094
Drug: Activated Charcoal with Sorbitol
RxNorm normalized name: Activated Charcoal with Sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05600114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT05132049
Drug: DA-5211-R1 + DA-5211-R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
Trial: NCT06562907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05157113
Drug: Dropless Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops.
Trial: NCT04758949
Drug: FL-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg administered intravenously every 2 weeks prior to surgery.
Trial: NCT04758949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg administered intravenously every 2 weeks prior to surgery.
Trial: NCT04860505
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
Trial: NCT04767815
Drug: Diet B group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes after a high-fat meal + DWN12088 200 mg
Trial: NCT05782894
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5\~12μg/kg/h
Trial: NCT06461390
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
Trial: NCT05957510
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the treatment recommended by the investigator
Trial: NCT05517655
Drug: 129Xe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
Trial: NCT06025344
Drug: PanCytoVir™ 100 mg/mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
Trial: NCT04815993
Drug: SYN-020 delayed release capsule
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Trial: NCT04763759
Drug: TRL1068, a human monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Trial: NCT05077475
Drug: C52R1H Tab. and C52R2 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
Trial: NCT05077475
Drug: AJU-C52L
RxNorm normalized name: AJUGA REPTANS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
Trial: NCT06064669
Drug: Metformin pretreatment before ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
Trial: NCT06064669
Drug: Placebo pretreatment before ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
Trial: NCT06064669
Drug: Metformin pretreatment before endometrial preparation for frozen embryo transfer
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Trial: NCT06064669
Drug: Placebo pretreatment before endometrial preparation for frozen embryo transfer
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Trial: NCT06109454
Drug: Huaier granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
Trial: NCT06697106
Drug: Nonsteroidal anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
Trial: NCT06697106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
Trial: NCT06698744
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m\^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
Trial: NCT06698965
Drug: Immunotherapy （Envafolimab）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
Trial: NCT04794972
Drug: GNC-039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion.
Trial: NCT05112549
Drug: Nivolumab [Opdivo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
Trial: NCT05532501
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
Trial: NCT05532501
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
Trial: NCT04790331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT04969666
Drug: IPED2015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment
Trial: NCT04969666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04955951
Drug: Topical corticosteroid ointment
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid 1 %.
Trial: NCT05179265
Drug: recombinant human serum albumin
RxNorm normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/bottle (20%, 50 mL)
Trial: NCT05488405
Drug: Mesalamine Oral Product
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine oral suspension for oral use
Trial: NCT04968509
Drug: PCSK9 inhibitors and statins with or without ezetimibe
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
Trial: NCT04968509
Drug: Statins with or without ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
Trial: NCT04813991
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg for breakthrough pain.
Trial: NCT04813991
Drug: OxyCODONE 5 Mg Oral Capsule
RxNorm normalized name: oxyCODONE 5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
Trial: 35932699
Drug: Robotic cat
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic cat therapy (20 min/week for 2 months)
Trial: 32542352
Drug: Active behavioral
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active behavioral Control Condition (CC)
Trial: 34561142
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines
Trial: 34751617
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) treatment
Trial: 33721566
Drug: Universal HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal HIV testing and treatment (UTT) via home-based HIV counselling and testing, linkage to care, promotion of ART adherence, and voluntary medical male circumcision.
Trial: 38320207
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine
Trial: 37422602
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose albumin
Trial: 39705390
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin
Trial: 32439008
Drug: Selatogrel 8
RxNorm normalized name: Selatogrel
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selatogrel 8 mg
Trial: 34337905
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (60,000 IU of colecalciferol monthly)
Trial: 33515070
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (7.5 mg with dose escalation to 67.5 mg)
Trial: 34818575
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (100 mg/kg body weight/day)
Trial: 32782111
Drug: Self-acupressure applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-acupressure applied to the TH-6 acupuncture point for 15 min twice a day for one week
Trial: 34231532
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment
Trial: 34587383
Drug: REGEN-COV 1200-mg
RxNorm normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: REGEN-COV 1200-mg
Trial: 35751108
Drug: Upadacitinib (UPA)
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib (UPA) 15 mg/day
Trial: 32736891
Drug: Linagliptin 5mg
RxNorm normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 5mg added to background insulin therapy
Trial: 38740499
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (LDN)
Trial: 38151311
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy
Trial: 33766820
Drug: Buccal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buccal midazolam (BM) administered by lay carers
Trial: 32985064
Drug: Low-dose THC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose THC (5 or 10 mg)
Trial: 39401872
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF)
Trial: 33711699
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF
Trial: 35057489
Drug: 11 g
RxNorm normalized name: PSMA-11 Ga 68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 g of BiotisTM GOS
Trial: 35867135
Drug: High albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High albumin + IVIG treatment group
Trial: 32007523
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light therapy (IPL) - four flashes
Trial: 33848338
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment D vs Placebo
Trial: 32222589
Drug: Cilostazol and
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol and aspirin
Trial: 33040610
Drug: onabotulinumtoxin-A (treatment)
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: onabotulinumtoxin-A (treatment)
Trial: 32349156
Drug: Nursing narratives
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing narratives with specific words (e.g., 'urination', 'food supply', 'bowel mobility', 'pain')
Trial: 35917774
Drug: Variable-rate infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable-rate infusion of norepinephrine
Trial: 35917774
Drug: Fixed-rate infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-rate infusion of norepinephrine
Trial: 34933684
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (0-28 days regimen)
Trial: 32408153
Drug: Calorie restriction
RxNorm normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie restriction (daily or intermittently)
Trial: 36278416
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group
Trial: 32637895
Drug: qHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHPV vaccine